Compare BNC & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNC | PROF |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.3M | 248.8M |
| IPO Year | 2010 | 2017 |
| Metric | BNC | PROF |
|---|---|---|
| Price | $5.34 | $5.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.14 |
| AVG Volume (30 Days) | ★ 835.4K | 264.5K |
| Earning Date | 09-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 159.72 | 25.89 |
| EPS | ★ N/A | N/A |
| Revenue | $9,581,968.00 | ★ $16,098,000.00 |
| Revenue This Year | $27.15 | $71.10 |
| Revenue Next Year | $6.70 | $58.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 32.89 | ★ 50.73 |
| 52 Week Low | $1.84 | $4.91 |
| 52 Week High | $7.99 | $8.95 |
| Indicator | BNC | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 52.72 | 40.05 |
| Support Level | $2.15 | $4.97 |
| Resistance Level | $5.58 | $7.19 |
| Average True Range (ATR) | 0.25 | 0.44 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 55.24 | 3.23 |
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.